April 9th – Mirum Pharmaceuticals: raising $120 million to develop therapies for rare liver disease

This BaselArea.swiss Life Science event will have Chris Peetz, CEO of Mirum Pharmaceuticals, talking about the story of the company and sharing insights and learnings along the way.

Mirum Pharmaceuticals – the most recent newcomer of the Basel ecosystem – is a late-stage biopharmaceutical company launched in 2018 with $120 million series A lead by New Enterprise Associates (NEA), and followed by Deerfield Management, Frazier, Novo Holdings A/S, Pappas Capital, RiverVest Venture Partners, and Rock Springs Capital.

The company licensed Maralixibat, a phase 3-ready Apical Sodium-dependent Bile acid Transporter Inhibitor (ASBTi) from Shire for treatment of Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), both debilitating genetic liver disorders affecting primarily children. Interestingly, Maralixibat had been brought in to Shire by their acquisition of Lumena Pharmaceuticals in 2014, a company that was also led by Mike Grey, CEO and executive chairman of Mirum Pharmaceuticals.

As part of the Shire deal, Mirum has also acquired the rights to Volixibat, similarly to Maralixibat, also a potential inhibitor of the apical sodium dependent bile acid transporter (ASBT). Volixibat, another ASBTi will be further investigated in adult cholestatic indications.

Please join us at this event on April 9th 2019, 18:30 to 20:00, at Halle 7, Dornacherstrasse 192, Basel.


Door opening




Chris Peetz, CEO Mirum Pharmaceuticals




Networking Apero

Participation to the event is free of charge; however, your registration by 8th April 2019 is kindly required.


Chris Peetz is chief executive officer and board member of Mirum Pharmaceuticals, bringing deep experience in therapeutic development and commercialization. He also serves as an entrepreneur-in-residence at Frazier Healthcare Partners, focusing on liver diseases and related therapeutic areas.

Previously, he served as chief financial officer and head of corporate development at Tobira Therapeutics, a leading developer of therapeutics to treat non-alcoholic steatohepatitis (NASH). While at Tobira, he led the company’s efforts to become a public company through a reverse merger, expand its pipeline through partnerships and in-licensing, and sell the company to Allergan for up to $1.7 billion. Prior to Tobira, Chris held business leadership roles at Jennerex Biotherapeutics, Onyx Pharmaceuticals and Abgenix. Chris holds a Bachelor of Science in Business Administration from Washington University in St. Louis and an MBA from the Stanford Graduate School of Business.